Stockreport

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) [Yahoo! Fi...

Genmab A/S - American Depositary Shares  (GMAB) 
PDF HNSCC is the sixth most common cancer worldwide, with incidence rates expected to increase 30% by 2030 i COPENHAGEN, Denmark, June 03, 2024 BUSINESS WIRE Genmab A/S ( [Read more]